The DSMB approval removes a key binary risk and de-risks the Phase I/II program, but CMND remains a pre-revenue micro-cap with high volatility. Monitor patient enrollment updates and any subsequent financing announcements given the $2M market cap.
Price Chart
Executive Summary
Clearmind Medicine received unanimous DSMB approval to advance its Phase I/II trial of CMND-100 for Alcohol Use Disorder to Parts B and C, following Part A's successful safety read. This is a positive clinical milestone for a micro-cap biotech, but the company remains pre-revenue with no near-term catalyst for revenue generation. The stock's historical volatility and poor prior call performance suggest caution despite the bullish signal.
Key Facts
- DSMB unanimously approved advancing Phase I/II trial of CMND-100 to Parts B and C
- Part A achieved primary safety endpoint with favorable tolerability across all dose levels
- Part B will evaluate CMND-100 in patients with moderate to severe AUD for the first time
- Part C will test 160 mg daily dose over 5 days in healthy participants in double-blind placebo-controlled segment
- Trial conducted at Johns Hopkins, Yale, Tel Aviv Sourasky Medical Center, and Hadassah Medical Center
Financial Impact
No financial data provided; pre-revenue clinical-stage biotech with $2M market cap
Risk Factors
- Clinical trial failure in Parts B or C
- Cash runway concerns given $2M market cap and pre-revenue status
- Regulatory and manufacturing risks for CMND-100
- Low liquidity and high volatility typical of micro-cap biotech stocks
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3340192 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 16, 2026 10d ago | 6-K | $6.00 | awaiting T+60 | — | $6.12 (−2.02%) |
Oct 13, 2026 13d ago | 6-K | $6.23 | awaiting T+60 | — | $6.12 (−1.75%) |
Oct 8, 2026 18d ago | 6-K | $6.60 | awaiting T+60 | — | $6.12 (−7.26%) |
Oct 7, 2026 19d ago | 6-K | $6.60 | awaiting T+60 | — | $6.12 (−7.26%) |
Sep 23, 2026 4w ago | 6-K | $0.8500 | awaiting T+60 | — | $6.12 (+620.12%) |
Sep 23, 2026 4w ago | Press Release | $0.8500 | awaiting T+60 | — | $6.12 (+620.12%) |
Sep 17, 2026 5w ago | Press Release | $6.86 | awaiting T+60 | — | $6.12 (−10.82%) |
Sep 14, 2026 6w ago | 6-K | $0.9440 | awaiting T+60 | — | $6.12 (+548.41%) |
Sep 8, 2026 6w ago | 6-K | $1.03 | awaiting T+60 | — | $6.12 (+494.27%) |
Sep 4, 2026 7w ago | 6-K | $1.16 | awaiting T+60 | — | $6.12 (−427.67%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers